Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor, Prashant MD 1; Ansell, Stephen M. MD; PhD 1; Fonseca, Rafael MD 2; Chanan-Khan, Asher MD 3; Kyle, Robert A. MD 1; Kumar, Shaji K. MD 1; Mikhael, Joseph R. MD 2; Witzig, Thomas E. MD 1; Mauermann, Michelle MD 4; Dispenzieri, Angela MD 1; Ailawadhi, Sikander MD 3; Stewart, A. Keith MBChB 2; Lacy, Martha Q. MD 1; Thompson, Carrie A. MD 1; Buadi, Francis K. MD 1; Dingli, David MD; PhD 1; Morice, William G. MD; PhD 5; Go, Ronald S. MD 1; Jevremovic, Dragan MD; PhD 5; Sher, Taimur MD 3; King, Rebecca L. MD 5; Braggio, Esteban PhD 2; Novak, Ann PhD 1; Roy, Vivek MD 3; Ketterling, Rhett P. MD 6; Greipp, Patricia T. MD 6; Grogan, Martha MD 7; Micallef, Ivana N. MD 1; Bergsagel, P. Leif MD; PhD 2; Colgan, Joseph P. MD 1; Leung, Nelson MD 1,8; Gonsalves, Wilson I. MD 1; Lin, Yi MD; PhD 1; Inwards, David J. MD 1; Hayman, Suzanne R. MD 1; Nowakowski, Grzegorz S. MD 1; Johnston, Patrick B. MD; PhD 1; Russell, Steven J. MD; PhD 1; Markovic, Svetomir N. MD; PhD 1; Zeldenrust, Steven R. MD; PhD 1; Hwa, Yi L. APRN; CNP; DNP 1; Lust, John A. MD; PhD 1; Porrata, Luis F. MD 1; Habermann, Thomas M. MD 1; Rajkumar, S. Vincent MD 1; Gertz, Morie A. MD 1; Reeder, Craig B. MD 2
3(9):1257-1265, September 2017.
(Format: HTML, PDF)
Importance: Waldenstrom macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system.
Observations: Waldenstrom macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course. The major classes of effective agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors, immunomodulatory drugs, and mammalian target of rapamycin inhibitors. However, the highest-quality evidence from rigorously conducted randomized clinical trials remains scant.
Conclusions and Relevance: Recognizing the paucity of data, we advocate participation in clinical trials, if available, at every stage of WM. Specific indications exist for initiation of therapy. Outside clinical trials, based on the synthesis of available evidence, we recommend bendamustine-rituximab as primary therapy for bulky disease, profound hematologic compromise, or constitutional symptoms attributable to WM. Dexamethasone-rituximab-cyclophosphamide is an alternative, particularly for nonbulky WM. Routine rituximab maintenance should be avoided. Plasma exchange should be promptly initiated before cytoreduction for hyperviscosity-related symptoms. Stem cell harvest for future use may be considered in first remission for patients 70 years or younger who are potential candidates for autologous stem cell transplantation. At relapse, retreatment with the original therapy is reasonable in patients with prior durable responses (time to next therapy >=3 years) and good tolerability to previous regimen. Ibrutinib is efficacious in patients with relapsed or refractory disease harboring MYD88 L265P mutation. In the absence of neuropathy, a bortezomib-rituximab-based option is reasonable for relapsed or refractory disease. In select patients with chemosensitive disease, autologous stem cell transplantation should be considered at first or second relapse. Everolimus and purine analogs are suitable options for refractory or multiply relapsed WM. Our recommendations are periodically updated as new, clinically relevant information emerges.
Copyright 2017 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.